PROGRESS AND PROBLEMS OF VACCINATION AGAINST CORONAVIRUS INFECTION COVID-19

Karatash A. V., Bilanova L. P., Bilash S. M., Pronina O. M., Bilash V. P., Hryn K. V., Hryn V. G., Oliinichenko Ya. O.

LITERATURE REVIEWS

Scentific article

. The pandemic of coronavirus infection caused by COVID-19 is an urgent problem today. Therefore, the search for optimal and safe ways to prevent the occurrence of this infection or its severe consequences is of great interest to scientists and clinicians worldwide. The most effective way to do this is vaccination, which, unfortunately, in the case of COVID-19, is only effective when the antigenic structure of the circulating virus matches the antigens contained in the vaccine. However, the emergence of new strains, due to the ability of the coronavirus to constantly change, which differ from circulating variants and have pandemic potential, leads to the ineffectiveness of previously proposed vaccines. Therefore, this work aimed to determine the main approaches to creating vaccines and the advantages and disadvantages of vaccination by conducting a bibliographic analysis of modern scientific publications. The main approaches to creating a vaccine against COVID-19 were characterized, in particular: vaccines based on an attenuated virus, inactivated vaccines, vector vaccines, protein vaccines, and vaccines based on nucleic acids. The main advantages and disadvantages of each of the proposed options are described. Considerable attention is paid to the issue of immunological imprinting and antibody-dependent enhancement of infection. A detailed analysis of these phenomena was carried out, and their influence on the effectiveness of various vaccines was described. It was established that the use of DNA and RNA vaccines, provided that the problem of their low immunogenicity in humans is solved, is a real alternative for the future development of medicine in the prevention of infectious diseases. The importance of considering the possibility of complications associated with the phenomena of antigenic imprinting and antibody-dependent enhancement of infection when developing vaccines and carrying out mass vaccinations has been proven. Since the complications underlying these phenomena can appear decades after the previous vaccination or epidemic. In addition, the vaccination itself, carried out without taking them into account, can complicate the epidemic process or cause the development of an epidemic of a closely related virus in those areas where this virus and the one against which the vaccination was carried out circulate at the same time.

vaccination,coronavirus infection,COVID-19,vaccine,immunological imprinting,antibodydependent enhancement of infection.

1. Al-Qahtani AA. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Emergence, history, basic and clinical aspects. Saudi J Biol Sci. 2020;10:2531-2538. DOI: 10.1016/j.sjbs.2020.04.033.
2. Hryn V, Kostylenko Y, Pinchuk V, Zhamardiy V, Donchenko V, Honchar O, et al. Experimental analysis of ways of viral infections into the human body. Wiad Lek. 2022;75(6):1544-1549. DOI: 10.36740/WLek2022 06121.
3. Yeroshenko GA, Koptev MM, Bilash SM, Shevchenko KV, Yachmin AI. Restructuring of rat lungs in acute immobilization stress and its correction. Svit medytsyny i biolohiyi. 2019;15(69):187-190.
4. Bilash SM, Bilash VP, Koptev MM, Deviatkina NM, Vynnyk NI, Filenko BM, Proskurnya SA, Roiko NV. Stress-Protected Effect of Torasemide in Acute Immobilization Stress in Rats. Journal of International Dental and Medical Research. 2021;2(14):806-811.
5. Vynnyk NI, Koptev MM, Sovhyrya SM, Filenko BM, Bilash SM. Current studies of Ukrainian researchers of stress impact on chest organs: literature review. Wiadomosci Lekarskie. 2017;LXX:1114-1117.
6. Yeroshenko HA, Bilash SM, Pronina OM, Koptev MM, Yachminʹ AI. Strukturni zminy nyrok shchuriv pry hostromu immobilizatsiynomu stresovi ta yikh korektsiya. Visnyk problem biolohiyi i medytsyny. 2019;3(152):294-7. [in Ukrainian].
7. Belouzard S, Millet JК, Beth NL, Whittaker GR. Mechanisms of Coronavirus Cell Entry Mediated by the Viral Spike Protein. Viruses. 2012;4:1011-1033. DOI: 10.3390/v4061011.
8. Shamray SM, Leontʹyev DV. Virusolohiya. KH.: Kharkivsʹkyy natsionalʹnyy pedahohichnyy universytet imeni H.S. Skovorody; 2019. 244 s. [in Ukrainian].
9. Supotnitskiy MV. Neissledovannyye tupiki vaktsinatsii. Krymskiy zhurnal eksperimental’noy i klinicheskoy meditsiny. 2011;1(3–4):118-127.
10. Yip MS, Cheung CY, Li PH, Bruzzone R, Peiris JSM, Jaume M. Investigation of Antibody-Dependent Enhancement (ADE) of SARS coronavirus infection and its role in pathogenesis of SARS. BMC Proc. 2011 Jan 10;5(1):P80.
11. Mironov OM, Supotnitsʹkyy MV, Lebedynsʹka OV. Fenomen antytilozalezhnoho posylennya infektsiyi u vaktsynovanykh i perekhvorilykh (chastyna II). Infektsiyni khvoroby. 2014;1:69-80. Dostupno: http://nbuv.gov. ua/UJRN/InfKhvor_2014_1_18y. [in Ukrainian].
12. Bilash SM, Pronina OM, Koptev MM. Comprehensive morphological studies as an intergal part of modern medical science. Literature review. Visnyk problem biolohiyi i medytsyny. 2019;2.2(151):20-23.
13. Koptev MM, NІ Vynnyk NI, Kokovska OV, Filenko BM, Bilash SM. The use of semi-thin section method in the study of stress-induced structural changes in lungs. Svit medytsyny i biolohiyi. 2018;2(64):153-156.
14. Vershyhora AYU, Paster YEU, Kolybo DV. Imunolohiya. K: Vyshcha shkola; 2005. 599 s. [in Ukrainian].
15. Supotnitskiy MV. Neugodnaya immunologiya. Aktual’naya infektologiya. 2016;2:73-97. Dostupno: http://nbuv.gov.ua/UJRN/akinf_2016 2 _12.
16. Jilani TN, Jamil RT, Siddiqui AH. H1N1 Influenza. Treasure Island (FL): StatPearls Publishing; 2021. Available from: .
17. Yip MS, Leung HL, Li PH, Cheung CY, Dutry I, Li D, et al. Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS. Hong Kong Med J. 2016 Jun;22(3(4)):25-31.
18. Vijayanand P, Wilkins E, Woodhead M. Severe acute respiratory syndrome (SARS): a review. Clin Med (Lond). 2004;4(2):152-60. DOI: 10.7861/clinmedicine.4-2-152.
19. Hu YL, Lee PI. Safety of Japanese encephalitis vaccines. Hum Vaccin Immunother. 2021 Nov 2;17(11):4259-4264. DOI: 10.1080/21645515. 2021.1969852.
20. Tariq N, Kyriakopoulos C. Group B Coxsackie Virus. Treasure Island (FL): StatPearls Publishing; 2021. Available from: .
21. Ananʹyeva MM, Knysh OV. Virus Ebola: patohenetychni aspekty ta pryntsypy laboratornoyi diahnostyky, napryamky imunoprofilaktyky. Aktualʹni problemy suchasnoyi medytsyny: Visnyk ukrayinsʹkoyi medychnoyi stomatolohichnoyi akademiyi. 2016;16(1(53)):282-290. [in Ukrainian].
22. Biagi C, Dondi A, Scarpini S, Rocca A, Vandini S, Poletti G, et al. Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines. Vaccines (Basel). 2020 Nov 11;8(4):672. DOI: 10.3390/vaccines8040672.
23. Leroux C, Cadoré JL, Montelaro RC. Equine Infectious Anemia Virus (EIAV): what has HIV’s country cousin got to tell us? Vet Res. 2004 Jul-Aug;35(4):485-512. DOI: 10.1051/vetres:2004020.
24. Hosie MJ, Pajek D, Samman A, Willett BJ. Feline immunodeficiency virus (FIV) neutralization: a review. Viruses. 2011 Oct;3(10):1870-90. DOI: 10.3390/v3101870.
25. Kostoff RN, Briggs MB, Porter AL, Spandidos DA, Tsatsakis A. [Comment] COVID-19 vaccine safety. Int J Mol Med. 2020 Nov;46(5):1599- 1602. DOI: 10.3892/ijmm.2020.4733.

«Bulletin of problems biology and medicine» Issue 3 (166), 2022 year, 50-58 pages, index UDK 616.9(COVID-19):35(075.8)

10.29254/2077-4214-2022-3-166-50-58